June 14, 2006 -- Pfizer bought the worldwide rights to lipid metabolism compounds from Bayer; Replidyne proposed terms for its upcoming IPO, giving itself a market cap of $394 million; CuraGen and TopoTarget began clinical testing of a cancer drug; Teva won tentative approval for a generic version of Merck’s Hyzaar; GTC received a $1 million milestone from LEO for ATryn; First Horizon Pharma got orphan drug status for a therapy aimed at chronic drooling in infants; and BioCryst Pharma out-licensed the South Korean rights for peramivir, its bird flu vaccine. At the closing bell, the Centient Biotech 200™ was up 16 points at 3571.57, a rise of .46%. More details...
